Form 4: Immunovant's Chief Medical Officer Sells Shares to Cover Tax Obligations
SEC Form 4
Michael Geffner, Immunovant's Chief Medical Officer, sold shares to cover tax withholding obligations related to the vesting of restricted stock units.
Summary
- Michael Geffner, the Chief Medical Officer of Immunovant, Inc., sold 3,456 shares of common stock on July 24, 2024.
- The shares were sold at a weighted average price of $27.76, with individual transactions ranging from $27.37 to $28.06 per share.
- The sale was mandated by Immunovant to cover tax withholding obligations associated with the vesting of 6,250 restricted stock units (RSUs) that vested on July 17, 2024, from a grant of 100,000 RSUs on January 17, 2023.
- Following the transaction, Geffner directly owns 138,160 shares of Immunovant common stock.
Sentiment
Score: 5
Explanation: The document reflects a routine transaction (sale of shares to cover taxes) and doesn't inherently indicate positive or negative sentiment.
Industry Context
Sales of shares to cover tax obligations upon vesting of restricted stock units are a common practice among company executives and employees.
Stakeholder Impact
- The sale of shares by an executive could have a minor impact on shareholder sentiment, but is unlikely to be significant given the reason for the sale.
Key Dates
| Date | Description |
|---|---|
| January 17, 2023 | Date of grant of 100,000 restricted stock units (RSUs). |
| July 17, 2024 | Date 6,250 of the RSUs vested. |
| July 24, 2024 | Date of the share sale transaction. |
| July 26, 2024 | Date of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.